OSTX: ostherapies.com Price/Earnings to Growth Multiple
Seeking to expand the OST-HER2 platform to capture the oncology market, OS Therapies Incorporated (OSTX) is developing immunotherapy for pediatric bone cancer. The undervalued growth company screener on GURU.Markets reflects the asset's dynamics, where the 0.00 value serves as the baseline indicator. Currently, the biotech firm is focusing on securing grants and establishing partnerships with Big Pharma to fund the final stages of clinical trials.
Metric breakdowns and analytics for OS Therapies Incorporated (OSTX)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital OS Therapies Incorporated|OSTX - Long-Term Debt to Equity|Current Liabilities to Capital ostherapies.com|OSTX - Company Debts|Debts to Net Assets OS Therapies Inc|OSTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings OS Therapies|Intermediate Liquidity Ratio ostherapies.com
- company profitability and valuation multiples indicators:
OSTX - Net Profit|Expected Net Income OS Therapies Incorporated|OSTX - P/E Multiple|Projected Price to Earnings Ratio OS Therapies, Inc.|OSTX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation OS Therapies Inc|OSTX - Operating profit EBITDA|Net earnings per share (EPS TTM) OS Therapies|OSTX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months ostherapies.com|OSTX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year OS Therapies Incorporated
Fundamental company analysis:OSTX, OS Therapies Inc.
When searching for undervalued assets, investors utilize this filter to evaluate the efficiency of growth value. The PEG ratio correlates the P/E market multiple with net profit growth rates to determine the premium paid for business dynamics. For OS Therapies Incorporated (OSTX), which is currently in the clinical trial phase, the calculation is based on expectations from future venture alliances. By analyzing the price-to-earnings-to-growth ratio, one can identify the potential for a "rocket" or the risk of inflated expectations.
Who OS Therapies Incorporated competes with
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Ratio Delcath Systems, Inc. (DCTH)|YMAB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Aura Biosciences AURA|Growth-Adjusted Market Cap to Net Income Candel Therapeutics Inc. (CADL)|ARAY: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc.) - Price/Earnings to Growth Multiple|CTOR: Company Value to Earnings Growth Ratio|HURA (TuHURA Biosciences Inc.) - PEG Multiple|TARA: Growth-Adjusted Payback Ratio|PEG Multiple FATE|WHWK - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio TScan Therapeutics, Inc. TCRX|Growth-Adjusted Payback Ratio CSBR|XBiotech USA - PEG Multiple|CVM - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - PEG Multiple|verupharma.com (VERU) - Growth-Adjusted Market Cap to Net Income|PEG Multiple TPST|XLO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Renovaro RENB|Growth-Adjusted Market Cap to Net Income Mural Oncology PLC (MURA)|KAPA: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio OKUR (OnKure Therapeutics Inc)|GDTC: PEG Multiple|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Apollomics Inc.|Growth-Adjusted P/E Ratio THAR (Tharimmune Corporation)|PEG Multiple ADVB|Price/Earnings to Growth Multiple genprex.com GNPX|Price/Earnings to Growth Ratio Calidi Biotherapeutics, Inc. CLDI|Sunshine Biopharma Inc. (SBFM) - Price to Earnings Adjusted for Growth Rate|XBIO - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio SLRX (Salarius Pharma)|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio AONC (American Oncology Network, Inc.)|Price/Earnings to Growth Ratio BeiGene|Price to Earnings Adjusted for Growth Rate Checkpoint Therapeutics Inc. CKPT|Price/Earnings to Growth Ratio Elevation Oncology, Inc. (ELEV)|ICAD (icadmed.com) - Growth-Adjusted Payback Ratio|PEG Multiple IKNA (Ikena Oncology)|PEG Multiple notablelabs.com NTBL|VIRX: Price/Earnings to Growth Multiple|MorphoSys Inc - Company Value to Earnings Growth Ratio|NAYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ascentage (AAPGV)
